Business
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
BOSTON, November 03, 2025--PureTech to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at ASH Annual Meeting
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/8a25df2bac78e785062eb616ec397fd5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gKB5nbvMDcl6awBkqDZcFQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8a25df2bac78e785062eb616ec397fd5","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xtnjvCzvnKOv.hUJwm_p9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8a25df2bac78e785062eb616ec397fd5","width":1200,"height":385}},"lazy":false},{"type":"text","content":"LYT-200 continues to demonstrate strong evidence of clinical activity, survival benefit and a highly favorable safety profile in heavily pretreated relapsed/refractory AML patients, both as a monotherapy and in combination with standard of care","length":244,"tagName":"p","attribs":{}},{"type":"text","content":"Compelling responses achieved in population with diverse tumor molecular subtypes","length":81,"tagName":"p","attribs":{}},{"type":"text","content":"Data continue to mature and will be presented during ASH 2025; topline efficacy readout and overall survival data expected in Q4 2025 and 1H 2026, respectively","length":159,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, November 03, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that new data from its ongoing Phase 1b clinical trial evaluating LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, in relapsed/refractory acute myeloid leukemia (AML) will be shared on December 6th, 2025, during the 67th Annual American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, by its Founded Entity Gallop Oncology. The accepted abstract reflects data as of July 8, 2025, and additional analyses based on a later data cut-off are expected to be presented during the ASH meeting.","length":789,"tagName":"p"},{"type":"text","content":"The ongoing, open-label, dose-ranging trial is evaluating LYT-200 both as a monotherapy an...